BIOMARCER-2

Protocol Title

BIOMARCER-2 – Biomarker informed optimal management of advanced RAS wild type colorectal cancer.

Purpose of the Study

Choosing the optimal therapy for patients with metastatic colorectal cancer is challenging. A number of factors are taken into consideration when selecting the most appropriate treatment plan, and include prior treatment, RAS/BRAF mutation status, mismatch repair status and primary tumour location.

This study will test colorectal tumour samples for a prognostic biomarker expression called amphiregulin (AREG) and epiregulin (EREG). These biomarkers indicate a possible sensitivity to cancer treatment known as anti-EGFR treatment. Patients who are determined to have high AREG and/or EREG expression levels for right sided RAS/BRAF wild-type, metastatic colorectal cancer will receive targeted treatment with anti-EGFR therapy. The study aims to demonstrate the progression free survival (PFS) benefit in those patients receiving anti-EGFR based treatment in the 2nd or later line setting.

Contact Email

agitg@gicancer.org.au

DETAILED INFORMATION AVAILABLE

Available online at the Australian New Zealand Clinical Trial Registry (ANZCTR) please click here.

STUDY CHAIRS

Dr Shehara Mendis
Professor Peter Gibbs

Funding

2021 Innovation Grant